Synopsis
The applicant, a 38-year-old maintenance mechanic and former U.S. Navy service member, faced security clearance denial under Guideline E (Personal Conduct) and Guideline H (Drug Involvement and Substance Misuse) due to a history of inappropriate conduct and drug use. The judge found that the applicant's admissions of past misconduct and false statements during the security clearance process raised significant concerns about his reliability and trustworthiness, leading to the denial of his security clearance.
Why the Applicant Was Denied
- The applicant admitted to providing false information in his security clearance questionnaire and during interviews with DoD investigators.
- The applicant's past conduct, including a confession to inappropriate touching of a minor, raised serious doubts about his judgment and reliability.
- The applicant's drug use, although legal under state law, was not sufficiently mitigated to alleviate concerns about his trustworthiness.
Conditions Referenced
- AG ¶ 16(a)appliedDeliberate Omission, Concealment, or Falsification of Relevant Facts
- AG ¶ 16(b)appliedDeliberately Providing False or Misleading Information
- AG ¶ 25(a)appliedAny Substance Misuse
- AG ¶ 25(c)appliedIllegal Possession of a Controlled Substance
- AG ¶ 17(c)appliedThe Offense Is so Minor, or so Much Time Has Passed, or the Behavior Is so Infrequent
- AG ¶ 26(a)appliedThe Behavior Happened so Long Ago, Was so Infrequent, or Happened Under Such Circumstances
- AG ¶ 26(b)appliedThe Individual Acknowledges His or Her Drug Involvement and Substance Misuse
Key Rule Quoted
“A person holding a security clearance has a duty to fully disclose conduct of security concern.”
Procedural Posture
- SOR issuedDec 27, 2024
- Answer filedJan 2, 2025Requested decision on the written record.
- Hearing held—No hearing; decided on written record.
- Decision dateMay 27, 2026
Cite For
- False Statements in Security Clearance Applications Under Guideline E
- Impact of Past Criminal Conduct on Security Clearance Eligibility
- Mitigation of Drug Involvement Concerns Under Guideline H